Baxter said it completed the sale of its Kidney Care business (Vantive) on January 31, 2025. The aggregate purchase price was $3.80 billion in cash. It said it received approximately $3.71 billion after adjustments and estimated the net after-tax proceeds at approximately $3.4 billion.

1. 01

   Baxter said it completed the sale of its Kidney Care business (Vantive) on January 31, 2025. The aggregate purchase price was $3.80 billion in cash. It said it received approximately $3.71 billion after adjustments and estimated the net after-tax proceeds at approximately $3.4 billion.

2. 02

   The company said the total closing cash consideration was $3,714 million, arrived at by adding an estimated cash adjustment of $169 million to the purchase price of $3,830 million, then deducting an estimated net working capital adjustment of $(49) million and estimated indebtedness at closing of $(236) million.

3. 03

   Baxter said that, assuming the sale and the Transition Agreements took effect on September 30, 2024, pro forma cash and cash equivalents would be $5,507 million, total assets would be $25,406 million and total capitalization would be $7,616 million.

4. 04

   The company said that for the full year 2023, pro forma net sales were $10,737 million, operating income was $904 million, net income from continuing operations attributable to Baxter stockholders was $339 million, and diluted income from continuing operations per share was $0.67.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.